Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03924193 · ClinicalTrials.gov registry record · Phase 3
Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Acute Treatment
A Phase 3 study of Obesity and Binge-Eating Disorder, sponsored by Yale University.
- Completed
- Registry status
- Phase 3
- Development phase
- 141
- Enrollment target
- 1
- Study location
NCT03924193: Completed Phase 3 study of Obesity and Binge-Eating Disorder, sponsored by Yale University.
NCT03924193 is a Phase 3 study of Obesity and Binge-Eating Disorder that has completed, run by Yale University. The registered enrollment target is 141 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03924193, a Phase 3 study of Obesity and Binge-Eating Disorder, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 141 participants
- Enrollment target
- 1
- Study location
Study Summary
Brief Summary: This study will compare the effectiveness of cognitive behavioral therapy (CBT), lisdexamfetamine (LDX), and the combination of CBT and LDX for the treatment of binge-eating disorder in patients with obesity. This is an acute treatment comparing CBT or LDX alone or in combination.
Primary Outcome
Binge eating will be assessed by interview and self-report and the primary outcomes is frequency. Frequency will be defined continuously (analyzed dimensionally).
Conditions Studied
Interventions
- DRUG Lisdexamfetamine Dimesylate
- BEHAVIORAL Cognitive-Behavioral Therapy
- OTHER Combination LDX and Cognitive-Behavioral Therapy
Study Locations (1)
Connecticut
- Yale Department of Psychiatry - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2019-03-25 |
| Est. Completion | 2023-09-13 |
| Phase | Phase 3 |
What the finished NCT03924193 record still lists
NCT03924193 is an interventional study that assigns participants to a tested intervention. The registered 141 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (83% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 3 interventions - of which Lisdexamfetamine Dimesylate is the first listed.
NCT03924193 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT03924193 about?
NCT03924193 is a clinical study titled "Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Acute Treatment". Brief Summary: This study will compare the effectiveness of cognitive behavioral therapy (CBT), lisdexamfetamine (LDX), and the combination of CBT and LDX for the treatment of binge-eating disorder in patients with obesity. This is an acute treatment comparing CBT or LDX alone or in combination.
What is the current status of trial NCT03924193?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 141 participants. The study started on 2019-03-25. Estimated completion is 2023-09-13.
What conditions does trial NCT03924193 study?
This clinical trial studies the following conditions: Obesity, Binge-Eating Disorder.
What interventions are being tested in trial NCT03924193?
The interventions under investigation include: Lisdexamfetamine Dimesylate (DRUG), Cognitive-Behavioral Therapy (BEHAVIORAL), Combination LDX and Cognitive-Behavioral Therapy (OTHER).
Who is sponsoring clinical trial NCT03924193?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03924193 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03924193's enrollment target sits among peer trials
141 399th of 1053 higher than 654 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03042962 · 141 participants
Brain Networks in Dystonia
- NCT04378439 · 141 participants · NA
Appalachian Partnership to Reduce Disparities (Aim 2)
- NCT04775485 · 141 participants · Phase 2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
- NCT05040360 · 141 participants · Phase 2
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI